Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,817.99 +11.29 0.40%
FTSE 100 6,723.06 +35.26 0.53%
DAX 8,398.00 +28.13 0.34%
Ticker Volume Price Price Delta
Nikkei 15,350.70 +212.57 1.40%
Hang Seng 23,472.20 +389.54 1.69%
S&P/ASX 200 5,210.80 +30.03 0.58%
  • Exchange: EN Brussels
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Therapeutics

ThromboGenics NV

+ Add to Watchlist

THR:BB

34.3500 EUR 2.8100 7.56%

As of 11:35:53 ET on 05/17/2013.

Company Profile for ThromboGenics NV (THR)

ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system.

Contact Information

ThromboGenics NV

Gaston Geenslaan 1
B-3001
Heverlee
Belgium
Phone: 32-16-75-13-10
Fax: 32-16-75-13-11

Key Executives for ThromboGenics NV (THR)

Desire CollenChairman/FounderPatrik De HaesCEO/Executive Director
Chris BuyseCFO/Executive Director/SecyKoen KasChief Scientific Officer
David PearsonHead:Country OperationsAndy De DeeneHead:Program Mgmt
Aniz GirachHead:Clinical OphthalmologyRam PalankiHead:Marketing
Laurence RaemdonckHead:Human ResourcesChristian JaeggiHead:Country Operations

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil